undamentalytics Newsletter

Renz Justin A: insider trades

Chief financial officer at 2 companies we cover. 1 open-market purchase and 14 sales not made under a pre-set plan, reported from April 6, 2015 to August 25, 2025.

Would copying Renz Justin A’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on April 7, 2015 into $3,755 by November 2, 2026, −8.1% a year. The copy held shares only 9% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $12,974, +2.3% a year (the S&P 500 held throughout made $44,096, +13.7% a year). Beta against the index was 0.13. Twelve months after each report, the average purchase was −72.7% against the S&P 500 (median −72.7%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −70.5%. After their sales, the shares moved −38.0% against the index over 12 months on average (a negative figure means selling was the right call); 88% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 201520172019202120232025 $44.1k$13.0k$3.8k
Copying Renz Justin AS&P 500, same days investedS&P 500, held throughout $10,000 copying Renz Justin A’s open-market purchases from April 7, 2015, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−8.1%
S&P 500, same days invested
+2.3% (held throughout +13.7%)
Time in shares
9%
Sharpe ratio (S&P 500)
−0.30 (0.69)
Biggest drop (S&P 500)
−85% (−34%)
Market sensitivity (beta)
0.13
Purchases copied
1

Trade by trade

Renz Justin A: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −17.9% −17.9% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 −59.3% −59.3% 0% 1 — — Not enough years
Purchases, 12 months after the report 1 −72.7% −72.7% 0% 1 — — Not enough years
Purchases, 12 months after the trade 1 −70.5% −70.5% 0% 1 — — Not enough years
Sales, 3 months after the report 8 −10.5% −14.0% 63% 4 −1.23 0.31 No reliable evidence
Sales, 12 months after the report 8 −38.0% −36.1% 88% 4 −1.88 0.16 No reliable evidence
Sales, 12 months after the trade 7 −47.3% −59.0% 100% 4 −2.24 0.11 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Ardelyx, Inc. ARDX Chief Financial Officer013September 17, 2020August 25, 2025
Karyopharm Therapeutics Inc. KPTI EVP, CFO & Treasurer11April 6, 2015November 14, 2016

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 25, 2025August 21, 2025 ARDX Sale $41,729 −15.2%−59.2%−60.2%
May 22, 2025May 20, 2025 ARDX Sale $29,449 not yetnot yetnot yet
February 21, 2025February 20, 2025 ARDX Sale $29,061 −19.9%+10.4%−12.6%
November 22, 2024November 20, 2024 ARDX Sale $25,195 +2.3%−5.3%not yet
August 22, 2024August 20, 2024 ARDX Sale $30,994 −25.3%−19.0%−17.1%
May 23, 2024May 21, 2024 ARDX Sale $40,354 −12.8%−53.2%−58.9%
February 22, 2024February 20, 2024 ARDX Sale $46,734 −18.2%−59.8%−63.1%
November 22, 2023November 20, 2023 ARDX Sale $12,526 not yetnot yetnot yet
August 23, 2023August 21, 2023 ARDX Sale $10,238 not yetnot yetnot yet
May 25, 2023May 23, 2023 ARDX Sale $10,486 not yetnot yetnot yet
February 24, 2023February 21, 2023 ARDX Sale $10,317 not yetnot yetnot yet
June 8, 2022June 6, 2022 ARDX Sale $47,638 not yetnot yetnot yet
September 17, 2020September 15, 2020 ARDX Sale $20,390 +3.9%−112.2%−112.8%
November 14, 2016November 9, 2016 KPTI Sale $35,561 +1.0%−5.5%−6.2%
April 6, 2015April 2, 2015 KPTI Purchase $148,550 −17.9%−72.7%−70.5%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Renz Justin A traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.